IFP Advisors Inc increased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 22.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,909 shares of the exchange traded fund’s stock after buying an additional 727 shares during the period. IFP Advisors Inc’s holdings in SPDR S&P Biotech ETF were worth $324,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in XBI. JPMorgan Chase & Co. lifted its position in shares of SPDR S&P Biotech ETF by 625.1% in the first quarter. JPMorgan Chase & Co. now owns 10,369,706 shares of the exchange traded fund’s stock valued at $840,983,000 after acquiring an additional 12,344,558 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of SPDR S&P Biotech ETF by 33.0% in the first quarter. Goldman Sachs Group Inc. now owns 13,524,858 shares of the exchange traded fund’s stock valued at $1,096,866,000 after acquiring an additional 3,353,029 shares in the last quarter. Simplex Trading LLC lifted its position in shares of SPDR S&P Biotech ETF by 116.1% in the first quarter. Simplex Trading LLC now owns 241,039 shares of the exchange traded fund’s stock valued at $19,548,000 after acquiring an additional 1,741,445 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of SPDR S&P Biotech ETF in the first quarter valued at $85,155,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new position in SPDR S&P Biotech ETF in the 1st quarter valued at about $48,660,000.
SPDR S&P Biotech ETF Trading Up 3.1%
NYSEARCA:XBI opened at $108.37 on Thursday. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97. The company’s 50-day moving average is $95.16 and its two-hundred day moving average is $86.21. SPDR S&P Biotech ETF has a 12-month low of $66.66 and a 12-month high of $108.62.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to invest in marijuana stocks in 7 steps
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Why Are These Companies Considered Blue Chips?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.